Skip to main content

Table 6 Change in panenterhino/Ge/08 assay viral load in nasal secretions - patients with quantifiable baseline viral load, ANCOVA-adjusted means

From: Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial

    I-C vs. placebo
  N Adjusteda mean (SE) Adjusteda mean (SE) differenceb 95 % CI p-value*
Baseline [log (copies/mL)]c      
 I-C 22 5.840 (0.200)    
 Placebo 24 6.139 (0.201)    
Change from baseline, [log (copies/mL)]      
 I-C 22 −1.007 (0.191) −0.453 (0.266) −0.990, 0.084 0.0958
 Placebo 24 −0.554 (0.183)    
Reduction from baseline (%)c,d      
 I-C 22 90.2    
 Placebo 24 72.0    
  1. CI confidence interval, SE standard error
  2. *For ANCOVA-adjusted comparison of placebo with I-C
  3. aThe means were adjusted for baseline viral load
  4. bA negative treatment difference favored I-C
  5. cBaseline values are unadjusted means
  6. dCalculated according to Eccles et al. [5]